Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Krystal Biotech ( (KRYS) ) is now available.
On July 24, 2025, Japan’s Ministry of Health, Labour and Welfare approved VYJUVEK® for treating dystrophic epidermolysis bullosa (DEB), marking it as the first genetic medicine for DEB in Japan. This approval allows flexible administration, including home dosing, and is based on a comprehensive clinical dataset showing positive outcomes. The approval is a significant milestone for Krystal Biotech, positioning them as a leader in genetic medicine for DEB and expanding their market presence in Japan, with commercial launch expected by the end of the year.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
Spark’s Take on KRYS Stock
According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.
Krystal Biotech receives a strong overall score due to its impressive financial performance and positive earnings call, highlighting robust revenue growth and strategic expansions. Technical indicators show moderate bullish momentum, while recent corporate events further bolster the company’s growth outlook. However, the relatively high P/E ratio suggests the stock could be overvalued, presenting a potential risk.
To see Spark’s full report on KRYS stock, click here.
More about Krystal Biotech
Krystal Biotech, Inc. is a global biotechnology company focused on the discovery, development, and commercialization of genetic medicines for diseases with high unmet medical needs. The company is known for VYJUVEK®, the first redosable gene therapy approved for the treatment of dystrophic epidermolysis bullosa in the United States, Europe, and Japan. Krystal Biotech is advancing a pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics.
Average Trading Volume: 362,062
Technical Sentiment Signal: Hold
Current Market Cap: $4.33B
Find detailed analytics on KRYS stock on TipRanks’ Stock Analysis page.